Volume 14, Issue 2 (2-2026)                   JoMMID 2026, 14(2): 130-136 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Lad B, Chavan S, Kadam T. Antibacterial Activity of Stigmatellin Y from Marine Bacillus amyloliquefaciens Against MDR Pseudomonas aeruginosa. JoMMID 2026; 14 (2) :130-136
URL: http://jommid.pasteur.ac.ir/article-1-770-en.html
Antibacterial Activity of Stigmatellin Y from Marine Bacillus amyloliquefaciens Against MDR Pseudomonas aeruginosa
Bhagvat Lad * , Sanjay Chavan , T.A. Kadam
School of Life Sciences, Swami Ramanand Teerth Marathwada University, Nanded, 431606, Maharashtra, India
Abstract:   (19 Views)
Introduction: Hospital-acquired infections caused by Pseudomonas aeruginosa strains frequently exhibit resistance to both monotherapy and combination therapy with antibiotics because of acquired and intrinsic resistance mechanisms. Therefore, there is an urgent need for novel and potent antibiotics to treat infections caused by multidrug-resistant (MDR) P. aeruginosa. Bioactive compounds from marine Bacillus species have the potential to inhibit the growth of MDR P. aeruginosa. Methods: In the present investigation, a Bacillus species was isolated from seawater using Zobell Marine Agar. The isolate was identified by morphological, biochemical, and 16S rRNA gene sequencing analyses. Ethyl acetate was used to extract extracellular bioactive secondary metabolites from the cell-free supernatant of the isolated strain. Column chromatography (silica gel, 100–200 mesh) was employed to further fractionate the crude extract, and the agar well diffusion method was used to assess antibacterial activity against MDR P. aeruginosa. The bioactive fraction F1 was putatively annotated using ultra-high-performance liquid chromatography–ultraviolet–mass spectrometry (UHPLC-UV-MS). Results: The marine bacterial isolate was identified as Bacillus amyloliquefaciens. The crude extract and its purified fraction F1 inhibited the growth of MDR P. aeruginosa. The column chromatography–purified bioactive fraction F1 showed zones of inhibition ranging from 15.0 to 16.7 mm against MDR P. aeruginosa. UHPLC-UV-MS analysis putatively annotated bioactive fraction F1 as stigmatellin Y, exhibiting a retention time of 28.50 min and a mass-to-charge ratio (m/z) of 507.2725 ([M+Na]⁺. Conclusion: This marine B. amyloliquefaciens strain produces the potent compound stigmatellin Y, which exhibits activity against MDR P. aeruginosa. This finding highlights the strain's potential as a source of novel therapeutic agents.
Keywords: Multidrug-resistant Pseudomonas aeruginosa, Stigmatellin Y, Marine Bacillus amyloliquefaciens, UHPLC-UV-MS
Full-Text [PDF 1114 kb]   (4 Downloads)    
Type of Study: Original article | Subject: Anti-microbial agents, resistance and treatment protocols
Received: 2025/08/26 | Accepted: 2026/02/21 | Published: 2026/09/7
References
1. Qin S, Xiao W, Zhou C, Pu Q, Deng X, Lan L, et al. Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. Signal Transduct Target Ther. 2022; 7 (1): 199. [DOI:10.1038/s41392-022-01056-1] [PMID] [PMCID]
2. Jesudason T. WHO publishes updated list of bacterial priority pathogens. Lancet Microbe. 2024; 5 (9): 100940. [DOI:10.1016/j.lanmic.2024.07.003] [PMID]
3. Althaferi RS, Alfouzan WA, Mustafa AS. Antibiotic resistance profile of clinical isolates of Pseudomonas aeruginosa obtained from Farwaniya Hospital in Kuwait using phenotypic and molecular methods. Antibiotics. 2025; 14 (6): 539. [DOI:10.3390/antibiotics14060539] [PMID] [PMCID]
4. Olsson A, Wistrand-Yuen P, Nielsen EI, Friberg LE, Sandegren L, Lagerbäck P, et al. Efficacy of antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa in automated time-lapse microscopy and static time-kill experiments. Antimicrob Agents Chemother. 2020; 64 (6): e01028-19. [DOI:10.1128/AAC.02111-19] [PMID] [PMCID]
5. Pang Z, Raudonis R, Glick BR, Lin TJ, Cheng Z. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv. 2019; 37 (1): 177-92. [DOI:10.1016/j.biotechadv.2018.11.013] [PMID] [PMCID]
6. Le TA, Hiba T, Chaudhari D, Preston AN, Palowsky ZR, Ahmadzadeh S, et al. Aminoglycoside-related nephrotoxicity and ototoxicity in clinical practice: a review of pathophysiological mechanism and treatment options. Adv Ther. 2023; 40 (4): 1357-65. [DOI:10.1007/s12325-023-02436-x] [PMID]
7. Wibowo JT, Bayu A, Ervira M, Septiana E, Simanjuntak P, Risdian C. Secondary metabolites from marine-derived bacteria with antibiotic and antibiofilm activities against drug-resistant pathogens. Mar Drugs. 2023; 21 (1): 50. [DOI:10.3390/md21010050] [PMID] [PMCID]
8. Boopathi S, Vashisth R, Manoharan P, Kandasamy R, Sivakumar N. Stigmatellin Y-an anti-biofilm compound from Bacillus subtilis BR4 possibly interferes in PQS-PqsR-mediated quorum sensing system in Pseudomonas aeruginosa. Bioorg Med Chem Lett. 2017; 27 (10): 2113-8. [DOI:10.1016/j.bmcl.2017.03.074] [PMID]
9. Başaran TI, Berber D, Gökalsın B, Tramice A, Tommonaro G, Abbamondi GR, et al. Extremophilic Natrinema versiforme against Pseudomonas aeruginosa quorum sensing and biofilm. Front Microbiol. 2020; 11: 79. [DOI:10.3389/fmicb.2020.00079] [PMID] [PMCID]
10. Raju R, Khalil ZG, Piggott AM, Blumenthal A, Gardiner DL, Skinner-Adams TS, et al. Mollemycin A: an antimalarial and antibacterial glyco-hexadepsipeptide-polyketide from an Australian marine-derived Streptomyces sp. (CMB-M0244). Org Lett. 2014; 16 (6): 1716-9. [DOI:10.1021/ol5003913] [PMID]
11. Maiti PK, Das S, Sahoo P, Mandal S. Streptomyces sp. SM01 isolated from Indian soil produces a novel antibiotic picolinamycin effective against multi drug resistant bacterial strains. Sci Rep. 2020; 10 (1): 10092. [DOI:10.1038/s41598-020-66984-w] [PMID] [PMCID]
12. Jacobs CS, Naicker R, Chenia HY. Quorum sensing inhibition by sponge-associated Bacillus species: suppressing Pseudomonas aeruginosa virulence factors. Antibiotics. 2025; 14 (10): 1035. [DOI:10.3390/antibiotics14101035] [PMID] [PMCID]
13. Kunze B, Kemmer T, Höfle G, Reichenbach H. Stigmatellin, a new antibiotic from Stigmatella aurantiaca (Myxobacterales) I. Production, physicochemical and biological properties. J Antibiot. 1984; 37 (5): 454-61. [DOI:10.7164/antibiotics.37.454] [PMID]
14. Boopathi S, Vashisth R, Mohanty AK, Jia AQ, Sivakumar N, Arockiaraj J. Bacillus subtilis BR4-derived stigmatellin Y interferes with Pqs-PqsR-mediated quorum sensing system of Pseudomonas aeruginosa. J Basic Microbiol. 2022; 62 (7): 801-14. [DOI:10.1002/jobm.202200017] [PMID]
15. Li H, Maimaitiming M, Zhou Y, Li H, Wang P, Liu Y, et al. Discovery of marine natural products as promising antibiotics against Pseudomonas aeruginosa. Mar Drugs. 2022; 20 (3): 192. [DOI:10.3390/md20030192] [PMID] [PMCID]
16. Skropeta D, Wei L. Deep-sea extremophiles: a new frontier for drug discovery. Future Med Chem. 2014; 6 (18): 2161-78.
17. Fenical W, Jensen PR. Developing a new resource for drug discovery: marine actinomycete bacteria. Nat Chem Biol. 2006; 2 (12): 666-73. [DOI:10.1038/nchembio841] [PMID]
18. Song B, Wang YZ, Wang GY, Liu GL, Li WZ, Yan F. The lipopeptide 6-2 produced by Bacillus amyloliquefaciens anti-CA has potent activity against the biofilm-forming organisms. Mar Pollut Bull. 2016; 108 (1-2): 62-9. [DOI:10.1016/j.marpolbul.2016.04.062] [PMID]
19. Sumner LW, Amberg A, Barrett D, Beale MH, Beger R, Daykin CA, et al. Proposed minimum reporting standards for chemical analysis: Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics. 2007; 3 (3): 211-21. [DOI:10.1007/s11306-007-0082-2] [PMID]
20. Okoth DA, Hug JJ, Garcia R, Müller R. Three new stigmatellin derivatives reveal biosynthetic insights of its side chain decoration. Molecules. 2022; 27 (14): 4656. [DOI:10.3390/molecules27144656] [PMID] [PMCID]
21. Gerth K, Müller R. Moderately thermophilic myxobacteria: novel potential for the production of natural products-isolation and characterization. Environ Microbiol. 2005; 7 (6): 874-80. [DOI:10.1111/j.1462-2920.2005.00761.x] [PMID]
22. Sansinenea E, Ortiz A. Secondary metabolites of soil Bacillus spp. Biotechnol Lett. 2011; 33 (8): 1523-38. [DOI:10.1007/s10529-011-0617-5] [PMID]
23. Chen XH, Koumoutsi A, Scholz R, Borriss R. More than anticipated-production of antibiotics and other secondary metabolites by Bacillus amyloliquefaciens FZB42. J Mol Microbiol Biotechnol. 2009; 16 (1-2): 14-24. [DOI:10.1159/000142891] [PMID]
24. Sangeetha D, Tharani J, Ishwarya R, Ramya P. Isolation and screening of marine bacterial isolates against clinical pathogens. Int J Curr Pharm Res. 2022; 14 (3): 53-7. [DOI:10.22159/ijcpr.2022v14i3.1987]
25. El-Newary SA, Ibrahim AY, Asker MS, Mahmoud MG, El Awady ME. Production, characterization and biological activities of acidic exopolysaccharide from marine Bacillus amyloliquefaciens 3MS 2017. Asian Pac J Trop Med. 2017; 10 (7): 652-62. [DOI:10.1016/j.apjtm.2017.07.005] [PMID]
26. Gao CH, Tian XP, Qi SH, Luo XM, Wang P, Zhang S. Antibacterial and antilarval compounds from marine gorgonian-associated bacterium Bacillus amyloliquefaciens SCSIO 00856. J Antibiot. 2010; 63 (4): 191-3. [DOI:10.1038/ja.2010.7] [PMID]
27. Dimkić I, Stanković S, Nišavić M, Petković M, Ristivojević P, Fira D, et al. The profile and antimicrobial activity of Bacillus lipopeptide extracts of five potential biocontrol strains. Front Microbiol. 2017; 8: 925. [DOI:10.3389/fmicb.2017.00925] [PMID]
28. Eloff JN. Which extractant should be chosen for the screening of antimicrobial activity of leaves? J Ethnopharmacol. 1998; 60 (1): 1-8. [DOI:10.1016/S0378-8741(97)00123-2] [PMID]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.